Short Interest in Replimune Group, Inc. Decreases By 16.5
REPL Stock | USD 12.51 0.02 0.16% |
About 57% of all Replimune's institutional investors are looking to take a long position. The analysis of the overall investor sentiment regarding Replimune Group suggests that some traders are interested. Replimune's investing sentiment shows overall attitude of investors towards Replimune Group.
Replimune |
Replimune Group, Inc. was the target of a significant decrease in short interest in November. As of November 30th, there was short interest totalling 5,580,000 shares, a decrease of 16.5 percent from the November 15th total of 6,680,000 shares. Based on an average daily trading volume, of 828,800 shares, the days-to-cover
Read at thelincolnianonline.com
Replimune Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards Replimune can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Replimune Fundamental Analysis
We analyze Replimune's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Replimune using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Replimune based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Number Of Shares Shorted
Number Of Shares Shorted Comparative Analysis
Replimune is currently under evaluation in number of shares shorted category among its peers. Number of Shares Shorted is the total amount of shares that are currently sold short by investors. When a stock is sold short, the short seller assumes the responsibility of repurchasing the stock at a lower price. The speculator will make money if the stock goes down in price or will experience a loss if the stock price goes up.
Replimune Group Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with Replimune stock to make a market-neutral strategy. Peer analysis of Replimune could also be used in its relative valuation, which is a method of valuing Replimune by comparing valuation metrics with similar companies.
Peers
Replimune Related Equities
MLYS | Mineralys Therapeutics, | 3.81 | ||||
VTYX | Ventyx Biosciences | 2.23 | ||||
AVTE | Aerovate Therapeutics | 1.56 | ||||
MRUS | Merus BV | 1.24 | ||||
NAMS | NewAmsterdam Pharma | 0.20 | ||||
NVCT | Nuvectis Pharma | 0.00 | ||||
CRNX | Crinetics Pharmaceuticals | 0.00 | ||||
ASND | Ascendis Pharma | 0.45 | ||||
UTHR | United Therapeutics | 0.76 | ||||
NUVL | Nuvalent | 1.00 | ||||
KRON | Kronos Bio | 1.53 | ||||
SNDX | Syndax Pharmaceuticals | 1.65 | ||||
KURA | Kura Oncology | 1.66 | ||||
PRTC | PureTech Health | 1.82 | ||||
KROS | Keros Therapeutics | 2.22 | ||||
GOSS | Gossamer Bio | 2.57 | ||||
LYRA | Lyra Therapeutics | 4.33 | ||||
PTGX | Protagonist Therapeutics | 5.45 |
Check out Replimune Hype Analysis, Replimune Correlation and Replimune Performance. You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Replimune. If investors know Replimune will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Replimune listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.04) | Return On Assets (0.27) | Return On Equity (0.50) |
The market value of Replimune Group is measured differently than its book value, which is the value of Replimune that is recorded on the company's balance sheet. Investors also form their own opinion of Replimune's value that differs from its market value or its book value, called intrinsic value, which is Replimune's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Replimune's market value can be influenced by many factors that don't directly affect Replimune's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Replimune's value and its price as these two are different measures arrived at by different means. Investors typically determine if Replimune is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Replimune's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.